Sodium glucose co‐transporter 2 inhibitors versus dipeptidyl peptidase‐4 inhibitors and the risk of ventricular arrhythmia among patients with type 2 diabetes: A population‐based cohort study
Main finding · VAResult — go to the resultHazard ratio 0.88 95% CI 0.71–1.07Authors' conclusion
SGLT2i use was not associated with the risk of VA among patients with type 2 diabetes.
Study context
- Population
- Patients with T2D, UK Clinical Practice Research Datalink Aurum linked to hospitalisation and vital statistics data
- Participants
- 88,516 matched patients
- Exposure
- SGLT2i vs DPP-4i use
- Outcome
- Ventricular arrhythmias (VA)
- Follow-up
- Mean 0.86 years
Methodological detailsprevalent new-user design, matched on diabetes treatment intensity, duration of prior DPP4i use, calendar time, sex, age and time-conditional propensity score
- Prevalent new-user design
- Matched on diabetes treatment intensity, duration of prior DPP4i use, calendar time, sex, age and time-conditional propensity score
Main finding
VA
Hazard ratio
0.88
95% CI 0.71–1.07
SGLT2ivs DPP4i
HR 0.88 (95% CI 0.71–1.07)
As reported in the abstract
- Ventricular arrhythmias (VA) events overall
- 385 (25.3 per 10 000 person-years)
Observational data: associations, not effects.
Secondary outcomes
| Outcome | HR (95% CI) | |
|---|---|---|
| VA, incident new users | 0.98 (0.76–1.27) | |
| VA, prevalent new users | 0.65 (0.46–0.92) | |
| Cardiac arrest | 0.64 (0.49–0.83) | |
| Fatal VAInconclusive due to sparse data | 1.76 (0.47–6.64) | |
| 0.10.31310Hazard ratio (log scale) |
Original publication
Sodium glucose co‐transporter 2 inhibitors versus dipeptidyl peptidase‐4 inhibitors and the risk of ventricular arrhythmia among patients with type 2 diabetes: A population‐based cohort study. Diabetes Obes Metab. Published 10 November 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →